Abrocitinib is a Janus Kinase Inhibitor. The mechanism of action of abrocitinib is as a Janus Kinase Inhibitor, and P-Glycoprotein Inhibitor.
*The following content is generated by AI and is for reference only.
Overview
Abrocitinib (CAS: 2091574-66-7) is a selective Janus kinase 1 (JAK1) inhibitor API. It is synthesized via multi-step organic coupling reactions to ensure high purity. Molecular formula: C22H25N7O.
Application
- Dermatology: Treatment of moderate-to-severe atopic dermatitis in adults.
- Pharmaceutical Manufacturing: Bulk supply for oral tablet formulation.
- Clinical Research: Active ingredient for Phase III efficacy trials.
Precautions
Contraindicated in patients with active infections or severe immunodeficiency. Store in a cool, dry place below 25°C protected from light. Handle with appropriate PPE to avoid inhalation or skin contact.